+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of dazodalibep in people with Sjgrens Syndrome. This phase 3 open-label study extends previous trials by continuing to monitor participants who completed 48 weeks of treatment with dazodalibep or placebo. The study is sponsored by Amgen and aims to better understand the safety profile of dazodalibep over an extended period. Participants who finished the initial 48-week trials HZNP-DAZ-301 or HZNP-DAZ-303 will receive an assigned dose of dazodalibep intravenously for an additional 132 weeks. This extension study involves a single treatment group receiving dazodalibep without placebo, focusing on ongoing treatment effects and participant safety. During the study, participants will be monitored for treatment-emergent adverse events for up to 152 weeks. Researchers will also measure the presence of anti-drug antibodies and plasma concentrations of dazodalibep for up to 132 weeks. Participants need to be available for all study visits and procedures, with safety assessments conducted regularly throughout the long-term extension period.

Age: 18Years +All GendersPhase 3
174 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of open-label iptacopan in adults with primary IgA nephropathy who have completed earlier clinical trials CLNP023X2203 or CLNP023A2301. This Phase III rollover extension program allows participants to continue treatment while gathering additional data on the drugs effects over time. The study aims to assess the ongoing impact of iptacopan on disease progression until marketing authorization or other specified conditions are met. Participants receive iptacopan capsules at a dose of 200 mg taken orally twice daily. Treatment continues until one of several conditions occurs, including completion of 3 years from the last participants first visit, loss of benefit as judged by the investigator, a change in the drugs benefit-risk profile, need for dialysis or kidney transplant, or drug availability through commercial channels. This open-label design provides continuous access to iptacopan while monitoring long-term effects. During the study, participants undergo safety assessments including monitoring for adverse events, vital sign changes, ECG abnormalities, and laboratory test results from the first dose until 7 days after the last dose. Efficacy evaluations are conducted every 6 months to track kidney function and proteinuria levels. The total participation period may last up to three years, offering detailed data on the drugs long-term safety and clinical impact in primary IgA nephropathy.

Age: 18Years - 100YearsAll GendersPhase 3
161 locations
E

Actively Recruiting

Immunoglobulin A nephropathy IgAN is a kidney disease where immune system proteins build up in the kidneys causing inflammation. This inflammation may lead to kidney damage over time and reduce kidney function. The study is evaluating how well mezagitamab changes protein levels in the urine compared to a placebo in adults with primary IgAN. It also aims to assess the safety and tolerability of mezagitamab and how it maintains kidney function long term compared to placebo. Participants are randomly assigned to one of two groups in the main study two-thirds will receive mezagitamab injections and one-third will receive placebo injections, both given subcutaneously for about 22 weeks. Additionally, an open-label group includes participants with varying protein levels or kidney function who receive mezagitamab similarly. The entire study lasts about 2 years, with treatment for 22 weeks followed by approximately 1.5 years of observation. During the study, participants will have regular clinic visits, including monthly check-ups during the observation period. Assessments include measuring changes in urine protein levels and kidney function over time. Safety and tolerability of the study drug will also be monitored throughout the trial. Participants may continue in the study for up to 104 weeks, with ongoing evaluations to track kidney health and proteinuria.

Age: 18Years +All GendersPhase 3
186 locations
C

Actively Recruiting

Researchers are evaluating empasiprubart compared to intravenous immunoglobulin IVIg for treating adults with Chronic Inflammatory Demyelinating Polyneuropathy CIDP. This Phase 3 study aims to assess the effectiveness and safety of these treatments in people who have responded to IVIg in the past and currently have active disease with residual disability. The study has two parts. In Part A, lasting 24 weeks, participants receive either empasiprubart plus a placebo resembling IVIg or IVIg plus a placebo resembling empasiprubart. After Part A, all participants enter Part B, a 96-week period where they receive empasiprubart without IVIg. Some participants also receive a placebo to maintain the blinding during Part A. Participants will be monitored through various assessments including changes in disability scores, grip strength, and quality of life measures at baseline and throughout the study periods. Researchers will also track adverse events, antibody formation against empasiprubart, and serum drug levels. Total participation spans approximately 120 weeks, including both study parts and ongoing evaluations.

Age: 18Years +All GendersPhase 3
107 locations
E

Actively Recruiting

Researchers are evaluating the accuracy and safety of the new Syai Tag system for continuous glucose monitoring in patients admitted to intensive internal care. With nearly 150,000 people in Slovenia living with diabetes, monitoring blood sugar levels closely is essential to prevent complications. This study involves patients in the intensive care unit who require blood sugar monitoring during their stay. Participants will have two small sensors placed on each upper arm to continuously measure blood sugar levels using the Syai Tag system, though these readings will not be visible to medical staff. At the same time, healthcare professionals will carry out routine blood sugar measurements. The study compares the accuracy of the continuous glucose monitoring system to standard blood sugar tests over the duration of the ICU stay, up to 14 days. During the study, researchers will monitor sensor uptime and compare glucose readings from the Syai Tag system to arterial blood gas measurements. They will also evaluate the impact of noradrenaline on measurement accuracy and the lifespan of the sensors in ICU conditions. The procedure is safe and painless, and patients will continue to receive the usual high-quality care throughout their participation.

Age: 18Years +All GendersPhase Not Applicable
1 location
A

Actively Recruiting

Researchers are investigating the relationship between renin levels and clinical outcomes in patients with vasoplegic shock, a severe condition characterized by low blood pressure that can lead to organ failure and death. This observational study focuses on adults with distributive shock who require high doses of noradrenaline and vasopressin but have not achieved adequate blood pressure despite fluid resuscitation. The study aims to understand which patients benefit most from synthetic angiotensin II and how renin concentrations before and after treatment relate to patient recovery. Patients with distributive shock who meet specific criteria will receive an infusion of synthetic angiotensin II starting at 20 ngkgmin, adjusted up to a maximum of 40 ngkgmin if needed. Blood samples to measure renin levels will be collected before starting the angiotensin II infusion and again six hours later. The study assesses the effects of angiotensin II on blood pressure and the need for other vasopressors. Participants will be monitored for organ failure-free days and ICU-free days over 28 days. Researchers will also evaluate the need for vasopressors, dialysis, mechanical ventilation, and changes in renin concentrations. The main outcome is the association between renin changes within six hours and 28-day organ failure-free days. The study will continue until 2027, with data collected on patient responses and clinical outcomes during this period.

Age: 18Years +All Genders
2 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effect of a multistrain probiotic called OMNi-BiOTiC4 Hetox on healing, pain management, and postsurgical complications following neurosurgery. This randomized controlled trial aims to determine if the probiotic improves patient-reported disability after neurosurgery by comparing it to a placebo. The study is led by University Maribor and focuses on adults who have undergone neurosurgery for conditions like disc herniation, stenosis, or spinal instability. Participants will be randomly assigned to receive either the OMNi-BiOTiC4 Hetox probiotic or a placebo. The probiotic contains several bacterial strains including Lacticaseibacillus casei W56, Lactobacillus acidophilus W37, and others, along with various supportive substances. The study involves a supplementation period lasting 4 weeks during which participants take the assigned dietary supplement. During the study, researchers will measure changes in disability using the Oswestry Disability Index ODI at 3 months after starting supplementation. Participants will undergo assessments and follow-up visits to monitor healing progress and any postsurgical complications. The trial includes safety monitoring to ensure no adverse reactions to the probiotic and has a total participation period covering at least 3 months after supplementation begins.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating epoetin alfa, a medication related to erythropoiesis stimulating agents, in critically ill trauma patients who require mechanical ventilation in intensive care units ICUs. This phase III, randomized, double-blind trial aims to see if epoetin alfa can reduce death rates and severe disability six months after injury. The study involves 2500 patients admitted to ICUs with primary trauma diagnoses from centers in Australia, New Zealand, Europe, and Saudi Arabia. Participants will receive either epoetin alfa 40,000 IU or a placebo sodium chloride 0.9% by subcutaneous injection on Study Days 1 and 8 while in the ICU. Treatment is administered during their ICU stay, and patients are randomly assigned to one of these two groups. The study is designed to compare the effects of epoetin alfa against placebo in this critically ill population. During the study, patients will be monitored for survival and disability outcomes using tools like the World Health Organization Disability Assessment Schedule WHODAS 2.0 at six months. Other outcomes include mortality at different time points and thrombotic vascular events. Data on clinical status, adverse events, and safety will also be collected. The total participation length includes ICU stay and follow-up assessments up to six months after injury.

Age: 18Years - 75YearsAll GendersPhase 3
41 locations
R

Actively Recruiting

Researchers are evaluating the real-world effectiveness of a fixed triple inhaled combination therapy called Trimbow 17259 g pMDI in adults with asthma. This study focuses on patients with severe asthma who have been treated for at least three years but still have uncontrolled symptoms despite using other inhaled therapies. The research aims to assess improvements in asthma symptom scores over six months after switching to Trimbow, as well as treatment adherence and lung function. The study is a multicenter, national, prospective, non-interventional design where patients are observed after their doctors independently decide to switch their inhaled therapy to Trimbow 17259 g pMDI. The recommended dose is two inhalations twice daily. Participants will be followed for six months, with assessments at enrollment, one month, and six months. If their asthma treatment changes away from Trimbow during the study, they are excluded. Other asthma medications and reliever inhalers are allowed as usual. Participants will attend three visits during routine clinical care where researchers will collect information on demographics, medical history, asthma control test ACT scores, lung function if available, medication adherence using a questionnaire, and any changes in asthma treatment. The main measure is the change in ACT score over six months. Secondary measures include lung function improvement and adherence to treatment. Safety and treatment changes are monitored throughout the study, which is expected to run from November 2024 to June 2026.

Age: 18Years +All Genders
18 locations
S

Actively Recruiting

Researchers are studying the use of point-of-care blood lactate testing as an addition to the Manchester Triage System MTS in emergency departments. The MTS is widely used but has moderate accuracy, particularly for children and older adults, and often leads to long wait times. This study focuses on patients categorized as yellow in the MTS, who have a 60-minute expected wait time, but may include some who need faster care. Elevated blood lactate levels, linked to higher risk, are being examined to improve triage precision and patient management. The study is a prospective, randomized trial involving two groups of patients with elevated capillary blood lactate levels from the yellow MTS category. Patients with normal lactate levels are excluded. One group will be re-triaged to the orange MTS category for more urgent treatment, while the control group remains in the yellow category without their lactate results being shared with the treating physician. Randomization is based on birth date, and the nurses know the lactate results while physicians remain blinded. Additional standard lab tests may be done later as needed. Participants will be followed for 30 days to assess outcomes such as the use of vasoactive drugs, in-hospital mortality, and ICU admissions. The study involves careful monitoring and double blinding to reduce bias. The goal is to see if adding lactate testing improves triage decisions and patient care in overcrowded emergency settings. The trial is sponsored by the University Medical Centre Maribor and is expected to run through the end of 2026.

Age: 18Years +All GendersPhase Not Applicable
1 location

1-10 of 18

1